Osteoporosis International

, Volume 29, Issue 12, pp 2761–2770 | Cite as

Bone mineral density in osteoporotic patients with pyogenic vertebral osteomyelitis: effect of early versus late treatment for osteoporosis

  • J. Kim
  • S.W. Kim
  • S.Y. Lee
  • T.-H. KimEmail author
  • J.-H. Jung
Original Article



Patients with pyogenic vertebral osteomyelitis (PVO) are at greater risk of bone loss. However, treatment guidelines for bone loss have been lacking. Early bisphosphonate treatment within 6 weeks after PVO diagnosis was significantly associated with superior outcome in femoral BMD at 2-year follow-up, compared to that with late treatment.


Due to absence of concern and proper guidelines, management of bone loss or osteoporosis in PVO is often neglected or delayed. A retrospective cohort study was planned to investigate differences in bone mineral density (BMD) in PVO patients with osteoporosis according to the timing of osteoporosis treatment.


The PVO cohort consisted of 192 patients with osteoporosis who visited our institution between January 2003 and March 2015 and received bisphosphonate treatment for osteoporosis. According to the interval between PVO diagnosis and initiation of bisphosphonate, the patients were divided into three groups: group A (within 6 weeks after PVO diagnosis), group B (between 6 weeks and 3 months after diagnosis), and group C (more than 3 months after PVO diagnosis).


The percent increase in total femoral BMD in group A was significantly larger than that in group B at 2-year follow-up (p = 0.036). Similarly, the percent increase in trochanteric (p = 0.008) and total femoral (p = 0009) BMD in group A was significantly larger than that in group C at 2-year follow-up. Even after multivariate adjustment, total femoral BMD changes were significantly associated with the treatment group. Group B (odds ratio = 2.824, p = 0.013) and group C (odds ratio = 3.591, p = 0.001) were more significantly associated with total femoral BMD decreases at 2-year follow-up compared with group A.


Early bisphosphonate treatment within 6 weeks after PVO diagnosis (group A) was significantly associated with superior outcome in femoral BMD at 2-year follow-up, compared to that with late treatment (groups B and C).


Bone loss Bone mineral density Osteoporosis Pyogenic Vertebral osteomyelitis 


Compliance with ethical standards

Conflicts of interest



  1. 1.
    Grammatico L, Baron S, Rusch E, Lepage B, Surer N, Desenclos JC, Besnier JM (2008) Epidemiology of vertebral osteomyelitis (VO) in France: analysis of hospital-discharge data 2002-2003. Epidemiol Infect 136(5):653–660CrossRefGoogle Scholar
  2. 2.
    Nickerson EK, Sinha R (2016) Vertebral osteomyelitis in adults: an update. Br Med Bull 117(1)CrossRefGoogle Scholar
  3. 3.
    Grammatico Guillon L, Baron S, Gettner S, Lecuyer AI, Gaborit C, Rosset P, Rusch E, Bernard L (2012) Bone and joint infections in hospitalized patients in France, 2008: clinical and economic outcomes. J Hosp Infect 82(1):40–48CrossRefGoogle Scholar
  4. 4.
    Kehrer M, Pedersen C, Jensen TG, Lassen AT (2014) Increasing incidence of pyogenic spondylodiscitis: a 14-year population-based study. J Infect 68(4):313–320CrossRefGoogle Scholar
  5. 5.
    Akiyama T, Chikuda H, Yasunaga H, Horiguchi H, Fushimi K, Saita K (2013) Incidence and risk factors for mortality of vertebral osteomyelitis: a retrospective analysis using the Japanese diagnosis procedure combination database. BMJ Open 3(3)CrossRefGoogle Scholar
  6. 6.
    Nickerson EK, Sinha R (2016) Vertebral osteomyelitis in adults: an update. Br Med Bull 117(1):121–138CrossRefGoogle Scholar
  7. 7.
    Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J (2012) Economic burden of periprosthetic joint infection in the United States. J Arthroplast 27(8):61–65 e61CrossRefGoogle Scholar
  8. 8.
    Bernard L, Dinh A, Ghout I, Simo D, Zeller V, Issartel B, Le Moing V, Belmatoug N, Lesprit P, Bru J-P (2015) Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial. Lancet 385(9971):875–882CrossRefGoogle Scholar
  9. 9.
    Grados F, Lescure FX, Senneville E, Flipo RM, Schmit JL, Fardellone P (2007) Suggestions for managing pyogenic (non-tuberculous) discitis in adults. Joint Bone Spine 74(2):133–139CrossRefGoogle Scholar
  10. 10.
    von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370(9596):1453–1457CrossRefGoogle Scholar
  11. 11.
    Nasto LA, Colangelo D, Mazzotta V, Di Meco E, Neri V, Nasto RA, Fantoni M, Pola E (2014) Is posterior percutaneous screw-rod instrumentation a safe and effective alternative approach to TLSO rigid bracing for single-level pyogenic spondylodiscitis? Results of a retrospective cohort analysis. Spine J 14(7):1139–1146CrossRefGoogle Scholar
  12. 12.
    Wood KB, Li W, Lebl DR, Ploumis A (2014) Management of thoracolumbar spine fractures. Spine J 14(1):145–164CrossRefGoogle Scholar
  13. 13.
    Kazakia GJ, Tjong W, Nirody JA, Burghardt AJ, Carballido-Gamio J, Patsch JM, Link T, Feeley BT, Ma CB (2014) The influence of disuse on bone microstructure and mechanics assessed by HR-pQCT. Bone 63:132–140CrossRefGoogle Scholar
  14. 14.
    Armbrecht G, Belavý DL, Backström M, Beller G, Alexandre C, Rizzoli R, Felsenberg D (2011) Trabecular and cortical bone density and architecture in women after 60 days of bed rest using high-resolution pQCT: WISE 2005. J Bone Miner Res 26(10):2399–2410CrossRefGoogle Scholar
  15. 15.
    Johnell O, Kanis J, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jönsson B (2004) Mortality after osteoporotic fractures. Osteoporos Int 15(1):38–42CrossRefGoogle Scholar
  16. 16.
    Ismail A, O’neill T, Cooper C, Finn J, Bhalla A, Cannata J, Delmas P, Falch J, Felsch B, Hoszowski K (1998) Mortality associated with vertebral deformity in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 8(3):291–297CrossRefGoogle Scholar
  17. 17.
    Michelson D, Stratakis C, Hill L, Reynolds J, Galliven E, Chrousos G, Gold P (1996) Bone mineral density in women with depression. N Engl J Med 335(16):1176–1181CrossRefGoogle Scholar
  18. 18.
    George J, Ganesh HK, Acharya S, Bandgar TR, Shivane V, Karvat A, Bhatia SJ, Shah S, Menon PS, Shah N (2009) Bone mineral density and disorders of mineral metabolism in chronic liver disease. World J Gastroenterol 15(28):3516–3522CrossRefGoogle Scholar
  19. 19.
    Schneider J, Fink H, Ewing S, Ensrud K, Cummings SR, Group SoOFR (2008) The association of Parkinson’s disease with bone mineral density and fracture in older women. Osteoporos Int 19(7):1093–1097CrossRefGoogle Scholar
  20. 20.
    Bolton CE, Ionescu AA, Shiels KM, Pettit RJ, Edwards PH, Stone MD, Nixon LS, Evans WD, Griffiths TL, Shale DJ (2004) Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170(12):1286–1293CrossRefGoogle Scholar
  21. 21.
    Berbari EF, Kanj SS, Kowalski TJ, Darouiche RO, Widmer AF, Schmitt SK, Hendershot EF, Holtom PD, Huddleston PM III, Petermann GW, Osmon DR (2015) Executive summary: 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis 61(6):859–863. CrossRefPubMedGoogle Scholar
  22. 22.
    Jean M, Irisson JO, Gras G, Bouchand F, Simo D, Duran C, Perronne C, Mulleman D, Bernard L, Dinh A (2017) Diagnostic delay of pyogenic vertebral osteomyelitis and its associated factors. Scand J Rheumatol 46(1):64–68CrossRefGoogle Scholar
  23. 23.
    McHenry MC, Easley KA, Locker GA (2002) Vertebral osteomyelitis: long-term outcome for 253 patients from 7 Cleveland-area hospitals. Clin Infect Dis 34(10):1342–1350CrossRefGoogle Scholar
  24. 24.
    Zerwekh JE, Ruml LA, Gottschalk F, Pak CY (1998) The effects of twelve weeks of bed rest on bone histology, biochemical markers of bone turnover, and calcium homeostasis in eleven normal subjects. J Bone Miner Res 13(10):1594–1601CrossRefGoogle Scholar
  25. 25.
    Morgan JL, Zwart SR, Heer M, Ploutz-Snyder R, Ericson K, Smith SM (2012) Bone metabolism and nutritional status during 30-day head-down tilt bed rest. J Appl Physiol. 01064.02012Google Scholar
  26. 26.
    Beller G, Belavý DL, Sun L, Armbrecht G, Alexandre C, Felsenberg D (2011) WISE-2005: bed-rest induced changes in bone mineral density in women during 60 days simulated microgravity. Bone 49(4):858–866CrossRefGoogle Scholar
  27. 27.
    Nair SP, Meghji S, Wilson M, Reddi K, White P, Henderson B (1996) Bacterially induced bone destruction: mechanisms and misconceptions. Infect Immun 64(7):2371–2380PubMedPubMedCentralGoogle Scholar
  28. 28.
    Greenspan SL, Maitland LA, Myers ER, Krasnow MB, Kido TH (1994) Femoral bone loss progresses with age: a longitudinal study in women over age 65. J Bone Miner Res 9(12):1959–1965CrossRefGoogle Scholar
  29. 29.
    Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ (1993) Effect of calcium supplementation on bone loss in postmenopausal women. N Engl J Med 328(7):460–464CrossRefGoogle Scholar
  30. 30.
    Smith SM, Zwart SR, Heer M, Lee SM, Baecker N, Meuche S, Macias BR, Shackelford LC, Schneider S, Hargens AR (2008) WISE-2005: supine treadmill exercise within lower body negative pressure and flywheel resistive exercise as a countermeasure to bed rest-induced bone loss in women during 60-day simulated microgravity. Bone 42(3):572–581CrossRefGoogle Scholar
  31. 31.
    LeBlanc AD, Driscol TB, Shackelford LC, Evans HJ, Rianon NJ, Smith SM, Feeback DL, Lai D (2002) Alendronate as an effective countermeasure to disuse induced bone loss. J Musculoskelet Neuronal Interact 2(4):335–343PubMedGoogle Scholar
  32. 32.
    Watanabe Y, Ohshima H, Mizuno K, Sekiguchi C, Fukunaga M, Kohri K, Rittweger J, Felsenberg D, Matsumoto T, Nakamura T (2004) Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest. J Bone Miner Res 19(11):1771–1778CrossRefGoogle Scholar
  33. 33.
    Sato Y, Asoh T, Kaji M, Oizumi K (2000) Beneficial effect of intermittent cyclical etidronate therapy in hemiplegic patients following an acute stroke. J Bone Miner Res 15(12):2487–2494CrossRefGoogle Scholar
  34. 34.
    Li CY, Price C, Delisser K, Nasser P, Laudier D, Clement M, Jepsen KJ, Schaffler MB (2005) Long-term disuse osteoporosis seems less sensitive to bisphosphonate treatment than other osteoporosis. J Bone Miner Res 20(1):117–124CrossRefGoogle Scholar
  35. 35.
    Berbari EF, Kanj S, Kowalski TJ et al (2015) 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis 61(6):e26–e46CrossRefGoogle Scholar
  36. 36.
    Pola E, Autore G, Formica VM, Pambianco V, Colangelo D, Cauda R, Fantoni M (2017) New classification for the treatment of pyogenic spondylodiscitis: validation study on a population of 250 patients with a follow-up of 2 years. Eur Spine J 26(Suppl 4):479–488CrossRefGoogle Scholar
  37. 37.
    Sato Y, Metoki N, Iwamoto J, Satoh K (2003) Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in stroke patients. Neurology 61(3):338–342CrossRefGoogle Scholar
  38. 38.
    Iwamoto J, Takeda T, Matsumoto H (2012) Sunlight exposure is important for preventing hip fractures in patients with Alzheimer’s disease, Parkinson’s disease, or stroke. Acta Neurol Scand 125(4):279–284CrossRefGoogle Scholar
  39. 39.
    Chastin SF, Mandrichenko O, Helbostadt J, Skelton DA (2014) Associations between objectively-measured sedentary behaviour and physical activity with bone mineral density in adults and older adults, the NHANES study. Bone 64:254–262CrossRefGoogle Scholar
  40. 40.
    Levesque M, Ndangang M, Riaudel T, De Decker L, Benichou J, Berrut G (2016) Relationship between body composition and bone mineral density, related to physical activity, in elderly women. Geriatr Psychol Neuropsychiatr Vieil 14(4):398–405PubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2018

Authors and Affiliations

  1. 1.Division of Infection, Department of Pediatrics, Kangdong Sacred Heart HospitalHallym University College of MedicineSeoulSouth Korea
  2. 2.Spine Center, Department of Orthopedics, Hallym University Sacred Heart HospitalHallym University College of MedicineAnyangSouth Korea

Personalised recommendations